Supplementary Table 1. Demographic and clinical characteristics of the pSS and HC cohorts.

	HC cohort (N=17)	pSS cohort (N=48)	p-value
Demographics			
Age (years), median [IQR]	41 [28, 44]	61.6 [55.5, 66.9]	<0.01
Female, n (%)	15 (88%)	43 (90%)	0.9
Disease duration (years)¶, median [IQR]	-	19.4 [14.4, 26.5]	-
Clinical parameters			
ESSDAI§, median [IQR]	-	8 [2, 15.5]	-
ESSDAI ≥5, n (%)	-	21 (58%)	-
Constitutional, n (%)	-	2 (6%)	-
Lymphadenopathy, n (%)	-	6 (17%)	-
Glandular, n (%)	-	12 (33%)	-
Articular, n (%)	-	14 (39%)	-
Cutaneous, n (%)	-	6 (17%)	-
Pulmonary, n (%)	-	10 (28%)	-
Renal, n (%)	-	2 (6%)	-
Muscular, n (%)	-	2 (6%)	-
PNS, n (%)	-	2 (6%)	-
CNS, n (%)	-	1 (3%)	-
Haematological, n (%)	-	8 (22%)	-
Biological, n (%)	-	14 (39%)	-
Associated lymphoma, n (%)	-	2 (4%)	-
Clinical laboratory data			
Anti-Ro52 (SSA) Ab +, n (%)	-	39 (85%)	-
Anti-Ro60 (SSA) Ab +, n (%)	-	40 (87%)	-
Anti-La (SSB) Ab +, n (%)	-	37 (82%)	-

Data are presented as median [IQR] or number (percentage).
¶ Data is missing for 26 patients.
§ Calculated in the 36 pSS patients in whom ESSDAI was assessed.
Ab: antibody; CNS: central nervous system; ESSDAI: European League Against Rheumatism Sjögren's syndrome Disease Activity Index; HC: Healthy control; IQR: interquartile range; PNS: peripheral nervous system; pSS: primary Sjögren's syndrome; SSA: Sjögren's syndrome antigen A; SSB: Sjögren's syndrome antigen B.